Oncolys BioPharma, Inc. (JP:4588) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolys BioPharma Inc. has completed enrollment for a Phase I clinical trial evaluating the safety and efficacy of their immunotherapy drug, Telomelysin (OBP-301), in advanced esophageal or gastro-esophageal cancer patients ineligible for surgery. This trial involves a combination of Telomelysin with chemoradiation and follows successful preliminary results in Japan, where Oncolys plans to submit a New Drug Application by end of 2024. The study’s completion marks a significant step towards potential new treatment options for these cancer patients.
For further insights into JP:4588 stock, check out TipRanks’ Stock Analysis page.